Recce Pharmaceuticals tests Covid treatment
Recce Pharmaceuticals will trial its anti-infective agents RECCE 327 and RECCE 529 against SARS- CoV-2. The company has teamed with North Carolina’s Path BioAnalytics to trial its broad-spectrum synthetic antibiotics which the company is commercialising to defeat resistant superbugs, Researchers at PBA will evaluate the company’s drug candidates in an ‘ex vivo respiratory organoid model…
Details










